论文部分内容阅读
[目的]观察拉米夫定加中药乙肝康治疗慢性乙型肝炎(CHB)的临床疗效及抗病毒作用。[方法]109例CHB患者随机分为3组,分别用拉米夫定、乙肝康、拉米夫定加乙肝康治疗。[结果]西药组、中药组和中西医结合组临床治愈率分别为35.6％、34.4％和59.4％(P<0.05);显效率分别为64.5％、65.7％和87.5％(P<0.05)。其抑制乙肝病毒(HBV)DNA的作用:中西医结合组>中药组>西药组。[结论]拉米夫定和中药乙肝康对HBV复制均有明显抑制作用,但两种药物协同应用的临床疗效及抗病毒作用均明显优于单用拉米夫定或乙肝康。
[Objective] To observe the clinical efficacy and antiviral effect of lamivudine plus Chinese medicine Hegan Kang on chronic hepatitis B (CHB). [Method] 109 CHB patients were randomly divided into 3 groups, treated with lamivudine, hepatitis B, lamivudine and hepatitis B, respectively. [Results] The clinical cure rates in the western medicine group, the traditional Chinese medicine group and the integrated traditional Chinese and western medicine group were 35.6%, 34.4% and 59.4%, respectively (P <0.05). The effective rates were 64.5%, 65.7% and 87.5%, respectively. Its inhibition of hepatitis B virus (HBV) DNA: Integrative Medicine Group> Chinese medicine group> Western medicine group. [Conclusion] Lamivudine and Herbal Medicine Hegagang can obviously inhibit the HBV replication. However, the clinical efficacy and antiviral effect of the two drugs in combination are obviously better than those of Lamivudine or.